Literature DB >> 24657399

Inflammation and portal hypertension - the undiscovered country.

Gautam Mehta1, Thierry Gustot2, Rajeshwar P Mookerjee1, Juan Carlos Garcia-Pagan3, Michael B Fallon4, Vijay H Shah5, Richard Moreau6, Rajiv Jalan7.   

Abstract

Portal hypertension has traditionally been viewed as a progressive process, involving ultrastructural changes including fibrosis, nodule formation, and vascular thrombosis, leading to increased intrahepatic resistance to flow. However, it is increasingly recognized that a significant component of this vascular resistance results from a dynamic process, regulated by complex interactions between the injured hepatocyte, the sinusoidal endothelial cell, the Kupffer cell and the hepatic stellate cell, which impact on sinusoidal calibre. Recent findings suggest these haemodynamic findings are most marked in patients with superimposed inflammation. The precise mechanisms for vascular dysfunction in cirrhosis with superimposed inflammation remain to be fully elucidated but several studies over the past decade have started to generate the hypothesis that inflammation may be a key mediator of the pathogenesis and severity of portal hypertension in this context. This review provides a comprehensive overview of the biological mechanisms for inflammation playing a key role in the severity of portal hypertension, and illustrates potential novel therapies that act by modifying these processes.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Inflammation; Liver failure; Portal hypertension; Variceal bleeding

Mesh:

Year:  2014        PMID: 24657399     DOI: 10.1016/j.jhep.2014.03.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  28 in total

Review 1.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

2.  Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis.

Authors:  Ping Liu
Journal:  Chin J Integr Med       Date:  2016-04-23       Impact factor: 1.978

Review 3.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.

Authors:  Georgios N Kalambokis; Gerasimos Baltayiannis; Dimitrios Christodoulou
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

5.  Non-selective beta blockers in cirrhosis: time to extend the indications?

Authors:  Dev Katarey; Rajiv Jalan
Journal:  Ann Transl Med       Date:  2019-12

6.  Abdominal infection reveals a rare disease.

Authors:  Clara Benedetta Conti; Mirella Fraquelli; Dario Conte
Journal:  Intern Emerg Med       Date:  2017-08-16       Impact factor: 3.397

Review 7.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 8.  Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.

Authors:  Alberto Ferrarese; Alberto Zanetto; Giacomo Germani; Patrizia Burra; Marco Senzolo
Journal:  World J Hepatol       Date:  2016-08-28

Review 9.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

10.  Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.

Authors:  Javier Michelena; José Altamirano; Juan G Abraldes; Silvia Affò; Oriol Morales-Ibanez; Pau Sancho-Bru; Marlene Dominguez; Juan Carlos García-Pagán; Javier Fernández; Vicente Arroyo; Pere Ginès; Alexandre Louvet; Philippe Mathurin; Wajahat Z Mehal; Juan Caballería; Ramón Bataller
Journal:  Hepatology       Date:  2015-04-13       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.